Ontario Cancer Institute, Princess Margaret Cancer Centre, Toronto, ON, Canada
Tian Qi Wang, Catherine Brown, Ashlee Vennettilli, Lauren Wong, Aein Zarrin, Aditi Dobriyal, Linda Chen, Vivien Pat, Anthea Ho, Valerie Ho, Cindy Xin, Hannah Solomon, Margaret Irwin, Christina Gonos, Zahra Merali, Wei Xu, Doris Howell, Geoffrey Liu
Background: In a busy chemo DC, any efficient means of tracking important chemotoxicities can improve quality of care. The study goal was to evaluate whether tablet technology available in a DC waiting room is able to capture prevalent and severe toxicities associated with chemotherapy using the patient reported outcome (PRO) - common toxicity criteria for adverse events (CTCAE). Methods: This cross-sectional PRO-CTCAE study of 160 adult solid/hematologic cancer outpatients of all stages, who were undergoing chemotherapy (CT), focused on common chemotoxicities captured using touchscreen tablets in the DC waiting room of Princess Margaret Cancer Centre (Toronto, CA). Individual health scores from the EQ-5D VAS tool and the prevalence of AEs experienced by cancer patients within the past seven days were captured. Symptoms that were listed as moderate to very severe were considered significant. Results: Across a wide range of tumours and patients on intravenous CT, the median age (range) was 56 (19-88) years; 38% were males.Patients reported a median (range) health score (100 = best health possible, 0 = worst) of 70 (4-100). The severity offiveprevalent, key side-effects of CT were tabulated (Table). 59% of patients felt their fatigue interfered significantly with their daily activities, and 30% felt decreased appetite interfered significantly. 32% experienced nausea occasionally to almost constantly. Conclusions: The common symptoms of CT were captured FEASIBLY, and found to be highly prevalent in this CT-treated population. Capturing additional symptom prevalence outside of the 7-day time frame may be important from a clinical standpoint. Administration of PRO-CTCAE instrument through tablet technology may be an excellent method to help collect such data systematically and reliably. Updated data on 300 patients will be presented at the meeting.
Symptoms | Moderate | Severe | Very severe | Total |
---|---|---|---|---|
Fatigue | 41% | 15% | 3% | 59% |
Decreased appetite | 27% | 12% | 5% | 42% |
Nausea | 19% | 6% | 3% | 28% |
Vomiting | 12% | 4% | 1% | 17% |
Mouth and throat sores | 9% | 8% | 0% | 17% |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Kohei Shitara
2022 ASCO Annual Meeting
First Author: Nancy E Avis
2024 ASCO Annual Meeting
First Author: Peter Trask
2019 ASCO Annual Meeting
First Author: Edward B. Garon